

# Viscosupplementation Market Recent Trends, Industry Analysis, Outlook, Insights, Share and Forecasts Report 2032

*viscosupplementation market is experiencing significant growth, driven by the rising prevalence of osteoarthritis*

VANCOUVER, BRITISH COLUMBIA, CANADA, July 8, 2024

/EINPresswire.com/ -- The global [viscosupplementation market](#) is experiencing significant growth, driven by the rising prevalence of osteoarthritis, a growing geriatric population, and increasing demand for minimally invasive treatment options.

According to a report by Emergen

Research, the market size was valued at \$4.41 billion in 2022 and is estimated to reach \$10.51 billion by 2032, reflecting a compound annual growth rate (CAGR) of 9.1% from 2022 to 2032.

## Market Overview

Viscosupplementation is a non-surgical procedure that involves injecting hyaluronic acid (HA) into a patient's arthritic joint, most commonly the knee. HA is a naturally occurring lubricant found in synovial fluid, which cushions and protects joints. Injections aim to replenish depleted HA, improving lubrication, reducing pain, and enhancing joint function.

To get more business strategists to request to sample copy@ <https://www.emergenresearch.com/request-sample/2773>

## Key Trends and Drivers

**Rising Prevalence of Osteoarthritis:** Osteoarthritis, a degenerative joint disease, is the leading cause of joint pain and disability globally. The increasing geriatric population is a major factor contributing to the rise in osteoarthritis cases. According to the Centers for Disease Control and Prevention (CDC), nearly half (49.6%) of adults aged 65 and older are diagnosed with arthritis.



**Growing Demand for Minimally Invasive Treatments:** Patients are increasingly opting for minimally invasive procedures like viscosupplementation due to quicker recovery times and fewer side effects compared to traditional joint replacement surgeries.

**Technological Advancements:** Advances in HA-based products with improved viscoelastic properties and sustained release mechanisms are propelling market growth.

## Restraints and Challenges

**High Treatment Costs:** The cost of viscosupplementation can be a barrier for some patients, especially without adequate insurance coverage.

**Reimbursement Policies:** Reimbursement policies for viscosupplementation procedures vary across regions, impacting patient access.

**Limited Clinical Evidence:** While research supports the effectiveness of viscosupplementation, some healthcare providers may require stronger long-term clinical data.

## Growth Opportunities

**Emerging Economies:** Rising disposable income and increasing healthcare awareness in emerging economies present significant growth opportunities for the viscosupplementation market.

**Increased Product Launches:** Leading players are actively developing and launching new viscosupplementation products with longer-lasting effects and improved delivery methods.

**Strategic Collaborations and Acquisitions:** Collaboration among key players in the healthcare industry for research, development, and distribution can further accelerate market expansion.

## SWOT Analysis

### Strengths:

Minimally invasive procedure with a proven safety profile

Effective treatment for pain management and improving joint function

Growing demand for non-surgical treatment options

### Weaknesses:

High cost of treatment

Limited long-term clinical data compared to some traditional treatments

Reimbursement challenges

### Opportunities:

Rising prevalence of osteoarthritis in a growing geriatric population

Untapped market potential in emerging economies

Technological advancements in HA-based products

Threats:

Stringent regulatory requirements for new product approvals

Increasing competition from alternative therapies

Potential for misuse or overuse of viscosupplementation procedures

Latest Strategic Developments and M&A Activity

On 17 September 2023, KiOmed Pharma and Arsylab, a French biotechnology company specializing in the design and marketing of innovative products to improve patients' quality of life, announced the strategic collaboration to enter the French market for promotion and distribution of KioMedineone, a new class of knee osteoarthritis treatment.

On 19 September 2022, Alkem Laboratories announced the regulatory approval of federal agency the Drug Controller General of India (DCGI) for the launch of StemOne, designated for treatment of Knee Osteoarthritis (OA) in collaboration with Stempeutics in India.

Learn More About The Key Segments Shaping This Market Download Free

Sample <https://www.emergenresearch.com/request-sample/2773>

Viscosupplementation Top Companies and Competitive Landscape

The global viscosupplementation market is fairly fragmented, with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective viscosupplementation solutions in the market.

Some major players included in the global viscosupplementation market report are:

Sanofi

Hoffmann-La Roche Ltd.

Anika Therapeutics, Inc.

Zimmer Biomet.

Bioventus

Fidia Farmaceutici S.p.A.

SEIKAGAKU CORPORATION

Chugai Pharmaceutical Co., Ltd.

OrthogenRx, Inc.

Miravo Healthcare

APTISSEN

LG Chem

AVNS

Smith+Nephew

Lifecore Biomedical, Inc.

Medical Device Business Services, Inc.  
Wellchem Pharmaceuticals Pte Ltd.  
Teva Pharmaceutical Industries Ltd.  
Labrha International  
Ferring B.V.

## Viscosupplementation Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global viscosupplementation market on the basis of dosage type, application, source, end-use, and region:

### Dosage Type Outlook (Revenue, USD Billion; 2019-2032)

Single Injection  
Three Injection  
Five Injection

### Application Outlook (Revenue, USD Billion; 2019-2032)

Knee Osteoarthritis  
Hip Osteoarthritis  
Hand/ Wrist Osteoarthritis  
Ankle/ Foot Osteoarthritis  
Shoulder Osteoarthritis  
Others

### Source Outlook (Revenue, USD Billion; 2019-2032)

Animal  
Non-animal

### End-use Outlook (Revenue, USD Billion; 2019-2032)

Hospitals  
Orthopedic Clinics  
Ambulatory Surgical Centers (ASCs)  
Others

### Regional Outlook (Revenue, USD Billion; 2019-2032)

North America  
U.S.  
Canada  
Mexico  
Europe  
Germany  
France

UK  
Italy  
Spain  
Benelux  
Rest of Europe  
Asia Pacific  
China  
India  
Japan  
South Korea  
Rest of APAC  
Latin America  
Brazil  
Rest of LATAM  
Middle East & Africa  
Saudi Arabia  
UAE  
South Africa  
Turkey  
Rest of Middle East & Africa

Eric Lee  
Emergen Research  
+91 90210 91709  
sales@emergenresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/725938209>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.